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ABSTRACT
Objective: The purpose of the current work was to characterize the mechanisms of cytotoxicity and mutagenesis of a potential human bladder 
carcinogen 2,6-dimethylaniline (2,6-DMA).
Methods: Chinese hamster ovary (CHO) AS52 cells were exposed to either human S9 activated 2,6-DMA for 6 h or its N-hydroxylamine and aminophenol 
metabolites for 1 h in serum-free medium. Cell survival was determined by trypan blue exclusion 24 h after treatment, and 6-thioguanine-resistant 
mutants at the xanthine-guanine phosphoribosyl transferase (gpt) gene locus were assessed with doses, of which relative survival is 30% or more. 
Nested polymerase chain reaction-based deletion analysis was also performed.
Results: AS52 cells exhibited a dose-dependent increase in cytotoxicity and mutant fraction on treatment of 2,6-DMA and its metabolites but 
show a considerable variation in potency with aminophenol metabolites having the highest potency and parent compound at least; at the highest 
2,6-dimethylaminophenol dose (10 µM), the mutant fraction in AS52 cells was 8-fold (13.2×10−5) greater than the spontaneous fraction of 1.62×10−5. 
Total deletion of the gpt gene sequences was found in 1 (4%) spontaneous and 2 (6%) the 6-thioguanine mutants generated by N-hydroxy-2,6-DMA.
Conclusions: These findings indicate the mutagenicity of 2,6-DMA at the gpt gene, which is mediated through hydroxylamine and aminophenol 
metabolites, and contribute to the elucidation of mechanisms through which 2,6-DMA may exert its effects in vivo.
Keywords: 2,6-Dimethylaniline, Metabolic activation, Genotoxicity, AS52/guanine phosphoribosyl transferase assay.
INTRODUCTION
2,6-Dimethylaniline (2,6-DMA), a well-known alkylanilines, is used as 
a chemical intermediate in the manufacture of pesticides, dyestuffs, 
antioxidants, pharmaceuticals, synthetic resins, fragrances, and 
other products [1,2]. Exposure to alkylaniline not only has been well 
documented in cigarette smokers [3] but also may occur from non-
smoking-related sources [4]. Smoking is associated with increased rates 
of bladder cancer [5]. Alkylanilines are believed to be the constituents 
of tobacco smoke that leads to the development of bladder cancer [6,7]. 
Several members of alkylanilines including 4-aminobiphenyl, 
2-naphthylamine, and benzidine, which are extensive, have been 
classified and regulated as human bladder carcinogens [8]. Other 
alkylaniline, including 2,6-DMA, have been implicated as possible 
human bladder carcinogens [6,9-12].
Genotoxicity of alkylanilines has received very limited investigation 
to date, and the fragmented available database supports only limited 
conclusions. Alkylaniline is metabolized to reactive alkylhydroxylamine 
which can undergo further bioactivation and conjugation 
reactions [13-15]. These reactions include those catalyzed by cytochrome 
P450-dependent monooxygenases and other enzymes; the free reactive 
hydroxylamine may be regenerated from the conjugated form in an 
acidic environment [13-15]. Possible metabolic pathways leading to the 
formation of genotoxic DMA damage products of 2,6-DMA are shown 
in Fig. 1. Recent results described here indicate that alkylaniline scan 
be potent genotoxins for cultured mammalian cells when activated 
by exogenous or endogenous Phases I and II xenobiotic-metabolizing 
enzymes [6,7,10-12,15]. However, there is little information available 
about mutagenicity of 2,6-DMA and a detailed metabolic profile of 2,6-
DMA. Moreover, it is not clear whether 2,6-DMA can induce the deletions 
and other gross structural changes in other types of cells. Therefore, 
there is of considerable interest to examine the toxic effects of 2,6-DMA 
in the reportedly more sensitive in vitro system for mutation assay.
For this reason, we have introduced a Chinese hamster ovary (CHO) 
AS52 cell line that carries a single copy of Escherichia coli xanthine-
guanine phosphoribosyl transferase (gpt) gene functionally expressed 
using SV40 early promoter and stably integrated into the AS52 cell 
genome [16]. AS52 cells were constructed by transfecting the plasmid 
vector pSV gpt into a normal X-linked mammalian HPRT-deficient CHO 
cells. The AS52 cell line has been demonstrated to be useful with regard 
to the detection of both deletion and point mutations at gpt, and the 
low spontaneous mutation fraction (MF) and the distinct advantage of 
carrying a small easily manipulated mutational target make the AS52 
cell line particularly suited to quantitative and molecular mutagenesis 
studies. The gpt structural gene is 456 base pairs (bp) with no 
introns versus a structural gene size of 654 bp for HPRT, which with 
introns comprises a genomic HPRT locus of approximately 35 kb [17]. 
Thus, AS52 cells are sensitive to induced mutagenesis by a variety 
of clastogens and radiomimetic agents that are often classified as 
nonmutagens in other assays [17]. The purpose of the present study 
was to characterize the mutational profile and mechanism induced by 
2,6-DMA in the gpt gene of AS52cells. We have tested the hypothesis 




All cell culture reagents were purchased from Lonza (Walkersville, 
MD). 2,6-DMA, 6-thioguanine (6-TG), dimethyl sulfoxide (DMSO), ethyl 
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methanesulfonate (EMS), and DL-isocitric acid were purchased from 
Sigma Chemical Co., St Louis, MO. 3,5-DMA and NADP were obtained 
from Acros Organics (Geel, Belgium) and Boehringer Mannheim 
(Indianapolis, IN), respectively.
Cell cultures
CHO AS52 cells, kindly provided by Dr. Gerald N. Wogan (Massachusetts 
Institute of Technology, Cambridge, MA, USA), were cultured in Ham’s 
F-12 medium supplemented with 100 units/mL penicillin, 100 µg/mL 
streptomycin, and 10% heat-inactivated fetal bovine serum (Atlanta 
Biologicals, Lawrenceville, GA) in a humidified atmosphere with 5% CO2 
at 37°C. Cells were cleansed of preexisting gpt mutants by culturing in 
MPA medium (10 µg/mL MPA, 250 µg/mL xanthine, 22 µg/mL adenine, 
11 µg/mL thymidine, and 1.2 µg/mL aminopterin) for 7 days and 
transferred for 3 days to medium enriched with xanthine (11.5 µg/mL), 
adenine (3 µg/mL), and thymidine (1.2 µg/mL) for recovery.
2,6-DMA treatment
Cells were placed in 6-well plates at a density of 0.5×106 cells per 
well the day before treatment. Cultures were, just before treatment, 
washed with phosphate-buffered saline (PBS) and refed with serum-
free medium containing human liver S9 mix (Moltox Inc., Boone, NC). 
Approximately 440 µg S9 protein (16 µL fraction) and 65 µL sterile-
filtered core mixture contained 25 mg/mL NADP and 45 mg/mL DL-
isocitric acid were added per ml of serum-free medium. Cells were 
exposed to 25, 50, 100, 250, 500, and 1000 µM of 2,6-DMA dissolved in 
DMSO for 5 h at 37°C, after which test compounds containing medium 
were removed and replated with fresh medium supplemented with 
10% FBS. The final concentration of DMSO to which cells µL were 
exposed was <0.1%.
Metabolite treatment
N-hydroxy and aminophenol metabolites of 2,6-DMA were synthesized 
as described previously [12]. The cells were seeded at 1×106 and 
incubated overnight with the regular medium. Then, medium changed 
to one without serum and cells were treated in triplicate with 5, 10, 25, 
50, 100, and 250 µM of N-hydroxy or aminophenol metabolites. After 
1 h treatment, the culture was washed with PBS, amended with Ham’s 
F-12 medium containing 10% FBS, and incubated.
Measurement of survival and gpt mutations
Cytotoxicity was determined by trypan blue exclusion assay 24 h 
after treatment, and the cells were maintained for full expression of 
the mutant phenotype. 7 days after treatment, 5×105 cells from each 
Fig. 3: Induced mutation fraction in AS52 cells treated with 
2,6-dimethylaniline, and its N-hydroxy and aminophenol 
metabolites, data represent mean ± standard deviation for three 
measurements
Fig. 1: Schematic representation of the presumed metabolic 
pathway for 2,6-dimethylaniline, Information was taken from Gan 
et al
Fig. 2: Dose dependent of cell survival after treatment with 
2,6-dimethylaniline, and its N-hydroxy and aminophenol 
metabolites in AS52 cells, Survival was determined by trypan 
blue assay 24 h after treatment, data represent mean ± standard 
deviation for three measurements
Fig. 4: Nested polymerase chain reaction (PCR) amplication of the 
gpt gene in AS52 cells. Two prominent bands at 0.5 (gpt structural 
gene) and 0.8 kb (rearranged pSV gpt gene) are observed in 
wild-type AS52 cells (WT), mutants generated by N-OH-2,6-DMA, 
rearranged pSV gpt band are present, but the PCR product for the 
structural gene is missing; 1kb ladders are shown in left lane
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group was placed in 100 mL of selection medium containing 10 µM 
6-TG and plated at 50,000 cells/10 mL/100 mm dish (10 dishes per 
group) for the determination of mutagenicity. Simultaneously with 6-TG 
selection, cells were seeded for the determination of plating efficiency 
(200 cells/10 mL/100 mm dish; 5 dishes per group). Colonies were 
scored after incubation for 14 days, and mutant fraction was calculated 
as the number of 6-TG mutants. The MF was calculated by dividing 
the number of mutants by the number of cells seeded and the plating 
efficiency. In one of the experiments, exposure to 8 mMEMS for 2 h was 
used as a positive control for mutation induction. Identified single gpt 
mutant colony was then grown to approximately 2×106 mutant cells for 
molecular analysis.
DNA isolation and polymerase chain reaction (PCR) deletion 
screening
Identified single gpt mutant colony was transferred to 24-well plates 
for propagating mutant cells. Approximately 2×106 mutant cells were 
collected for molecular analysis. Genomic DNA was extracted from 
each mutant using a GenEluteTM mammalian genomic DNA miniprep 
kit (Sigma). Amplification of the gDNA was performed in two rounds of 
nested PCR in PTC-200 DNA Engine Thermal Cycler (Bio-Rad, Hercules, 
CA). About 1 µg of template DNA was transferred into the first round 
mix of 10 µL 10× PCR buffer, 2 µL dNTP mix, 0.5 µL taq polymerase, 
73.5 µL high-performance liquid chromatography water, 0.2 µL each 
25 mM forward (bases - 199 to - 181; 5’-AAGCTTGGACACAAGACAG-3’) 
and reverse (bases 520 to 540; 5’-CCAGAATACTTACTGGAAAC-3’) 
primer and amplified with a PCR profile of 94°C: 1 min, 30 cycles of 
94°C: 1 min, 47°C: 1 min, 72°C: 1 min and a final extension of 72°C 
for 7 min. The product from this reaction was filtered using Centricon 
50 concentrator (Amicon, Beverly, MA) and resuspended in 100 µL 
sterile water to avoid unspecific binding with remaining primers, and 
10 µL aliquot was used as template in the second round of PCR using 
nested primers (bases -23 to -4; 5’-ATAAACAGGCTGGGACACTT-3’ 
and bases 460 to 470; 5’-AGTGCCAGGCGTTGAAAAGA-3’). The PCR 
conditions were the same in the second round as those in the first 
round reaction, except annealing temperature (52°C). A quantity of gpt 
gene amplification was analyzed by electrophoresis on 1% agarose gels 
stained with ethidium bromide.
RESULTS AND DISCUSSION
Survival and MFs
Alkylaniline toxicity is characterized by methemoglobin formation 
and by hyperplasia and siderosis of the spleen [18]. The compound 
is nonmutagenic in the standard Salmonella typhimurium/microsome 
test [19]. It is positive, however, in inducing DNA damage in the liver 
and kidney of rats and in inducing sister chromatid exchanges in vivo 
in mice [20]. Alkylaniline, at a high concentration, induces minimal 
increases in sister chromatid exchanges in vitro [21] and forms DNA 
adducts [6,11]. Mutagenic activity of a chemical is a function of both the 
capacity to adduct DNA and the capacity of the cell to respond to the 
damage. DNA adducts formed from distinct alkylanilines have already 
been shown to be differentially mutagenic [22].
In the present study, all test compounds reduced the cell survival, 
whereas they increased the proportion of cells carrying the mutated 
gpt gene in a dose-dependent manner (Figs. 2 and 3). The survival 
of the test cell lines following 2,6-dimethyaminophenol (2,6-DMAP) 
treatment was lower than that observed in the corresponding 
N-hydroxy metabolite and parent compound; for instance, cell viability 
was 3% in AS52 cells 24 h after a dose of 50 µM 2,6-DMAP, compared 
to 69% and 85% after treatment with N-hydroxy-2,6-DMA (N-OH-2,6-
DMA) and 2,6-DMA, respectively (Fig. 2).
Previous studies showed that, if the relative survival rate is 30% or 
more after chemical exposure, there will be sufficient live cells to 
determine mutation responses [23,24]. Thus, based on the results of 
cytotoxicity experiment, three cultures with those concentration ranges 
for 2,6-DMA (25–500 µM), N-OH-2,6-DMA (5–100 µM), and 2,6-DMAP 
(5 and 10 µM) were used to determine mutagenic responses (Fig. 3). 
When cells were treated with 100 µM of 2,6-DMA and N-OH-2,6-DMA, 
MF was 5.01×10−5 and 7.17×10−5, 3- and 4.5-fold the spontaneous MF 
(1.61×10−5), respectively. On the other hand, 5 µM 2,6-DMAP, which 
is 20 times lower concentration, enhanced the MF from 1.61×10−5 to 
6.48×10−5 (Fig. 3). By comparison, in EMS-treated positive controls, MF 
at the gpt locus was 72.7×10−5.
Our results correlated well with that obtained by previous studies 
showing both phase I and phase II metabolism are required for 
genotoxic-specific activation of 2,6-DMA. Nohmi et al. reported the 
presence of the mutagenic N-hydroxylated metabolite of 2,4-DMA in 
an in vitro rat liver microsomal system (S9) in which the yield of the 
mutagenic metabolite increased with increasing S9 content [25]. Beland 
et al. reported the mutagenicity of the N-hydroxylated metabolite of 
2,6-DMA toward S. typhimurium (TA100) [26].
Deletion screening of AS52gpt mutants
Thirty-five independent 500 µM 2,6-DMA and 100 μM N-OH-2,6-DMA, 
34 independent 10 μM 2,6-DMAP, and 24 independent spontaneous 
6-TG-resistant mutants in AS52 cells were isolated and analyzed by the 
nested PCR, to test for the presence or absence of the gpt structural gene 
(0.5 kb PCR product) and the closely linked rearrangement product of 
this gene (0.8 kb PCR product). Those 6-TG-resistant mutants with both 
PCR sequences intact are mostly likely to carry point mutations in the 
gpt structural gene. Loss or alteration of one or both bands suggests 
more complex chromosomal deletions [27] and/or rearrangements 
involving gpt [28,29].
Screening results of the gpt gene deletions showed that the percentage of 
deletion mutations in the spontaneous gpt mutants was 4% (1 of 24): That 
of the 100 μMN-OH-2,6-DMA-enhanced mutants was 6% (2 out of 35) 
(Table 1 and Fig. 4). The mechanisms for the gene deletion are complicated 
and may involve different pathways such as DNA strand breakage, error 
in DNA damage repair, and other kinds of DNA damages [30]. Deletion of 
the gpt genein N-OH-2,6-DMA-enhanced mutants may be result from DNA 
damage caused by high cytotoxicity of the chemical.
CONCLUSION
The results reveal that 2,6-DMA is mutagenic and genotoxic in gpt gene 
of AS52 cells when activated by Phases I and II metabolism, in which 
the aminophenol metabolites were considerably more potent than 
the corresponding N-hydroxylamines. Further study is also needed to 
investigate the mechanism of genotoxic activity of 2,6-DMA.
Table 1: PCR analysis of gpt in AS52 Cells after treatment with 2,6-DMA and its metabolites
Spontaneous 2,6-DMA N-OH-2,6-DMA 2,6-DMAP
No observable alterationa 23 (96) 35 (100) 33 (94) 34 (100)
Large deletions/rearrangementsb 1 (4) 0 (0) 2 (6) 0 (0)
Total of mutants analyzed 24 (100) 35 (100) 35 (100) 34 (100)
aNo alterations were observable in the migration of the primary PCR products of the structural gpt gene on an agarose gel as compared to the AS52 wild-type control, 
bLarge deletions or rearrangements resulting in the absence of PCR amplified gpt sequences (complete deletions [0.5+0.8 kb] and deletions of the 0.5 kb with normal 
0.8 kb product), PCR: Polymerase chain reaction
Number of mutants (%)
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